PMC9440701_01
Treatment history and CT images of three lesions during the treatments. (A) Timeline of treatments and timepoints of NGS sample collections are shown. CT images of (B) the upper lobe of right lung, (C) the right hilum lesion, and (D) the mediastinal lymph nodes during the treatments. Tumors are indicated by red arrows.
OTT-15-919-g0001.jpg
PMC9440701_01_OTT-15-919-g0001.jpg
f0001
Positron emission tomography-computed tomography (PET-CT) scan indicated a 14x9 mm density mass in the upper lobe of right lung and a 23x7 mm density mass in the right hilum, respectively (Figure 1). In November 2017, the lesions in the upper lobe of right lung deceased to 14x4 mm, the size of the right hilum lesion increased to 27x14 mm and a new 11x8 mm density mass in the mediastinal lymph nodes occurred (Figure 1). In July 2018, the size of the upper lobe of right lung and right hilum lesion increased to 18x13 mm and 65x36 mm, respectively, which indicated a PD (Figure 1). However, the size of the upper lobe of right lung, mediastinal lymph nodes and right hilum lesion increased to 18x17 mm, 15x12 mm and 110x80 mm, respectively, which indicated a PD (Figure 1) and targeted NGS revealed EGFR L718Q (MAF =1.6%), EGFR T790M (MAF = 0.8%), EGFR L858R (MAF = 3.4%) and TP53 R282W (MAF = 37.7%) in the plasma sample in December 2018 (Table 1).